Contents and significance of secondary development of large varieties of traditional Chinese medicines  

作　　者：Wenlong Li Youth Editorial Board Member of CHM 

机构地区：[1]College of Pharmaceutical Engineering of Traditional Chinese Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China [2]State Key Laboratory of Component-based Chinese Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China [3]Haihe Laboratory of Modern Chinese Medicine,Tianjin 301617,China [4]不详

出　　处：《Chinese Herbal Medicines》2023年第2期155-156,共2页中草药（英文版）

摘　　要：Large variety of traditional Chinese medicines(TCMs)refers to the traditional Chinese medicines that have achieved large-scale production and undergone long-term clinical trials,proving to have ideal clinical value and market prospects.However,these medicines are limited by the technological capabilities at the time registration,always leading to the possible problems such as insufficient research into raw materials,unclear clinical mechanisms,backward manufacturing techniques and relatively low quality standards.Consequently,a more extensive and systematic research effort is needed,as well as a comprehensive improvement of the raw materials,manufacturing processes,and quality standards,in order to raise the quality of products and provide better service to the public.The research mentioned above is known as the secondary development of large variety of TCMs,which specifically includes the following four parts of contents.

关 键 词：MEDICINES BACKWARD mentioned 

分 类 号：R288[医药卫生—中药学]